Loading
Antibiotics given in the weeks before immunotherapy are linked to much worse results. A simple stewardship rule could preserve benefit at no cost.
Multiple cohort studies and meta-analyses report substantially worse survival in patients receiving broad-spectrum antibiotics within roughly 30 days before checkpoint blockade. Causality is uncertain because antibiotic use marks infection and frailty. A stewardship intervention (narrow-spectrum choice, shortest effective duration, deferral of non-urgent prophylaxis, and where necessary delaying checkpoint start) is testable and cheap either way.
Shares Laurence Zitvogel, Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No incentive to repurpose cheap drugs.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma.
Shares Laurence Zitvogel, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma.
Shares Laurence Zitvogel, Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial, Probiotics, antibiotics and stewardship around immunotherapy, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares No incentive to repurpose cheap drugs, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No incentive to repurpose cheap drugs, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma.